Private investment in Swiss biotechs reached a record CHF 1.15 billion in 2025, increasing 38% versus 2024, according to Swiss biotech tracking data. The report also said the 2025 figure represented 45% of total sector capital raised, indicating a shift toward more private-stage funding. The funding growth coincided with higher employment across the sector, suggesting renewed confidence in venture and private capital participation rather than a one-off public market rebound. For companies seeking runway and platform validation, the Swiss results reinforce that regional ecosystems can sustain funding activity even as global dealmaking remains selective. Biotech leaders will likely view the statistics as evidence that investor appetite for validated platforms and clinical momentum can return, particularly when manufacturing, regulatory, and go-to-market execution are credible.